{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T04:35:50Z","timestamp":1767414950767,"version":"3.38.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.ejpb.2011.01.006","type":"journal-article","created":{"date-parts":[[2011,2,4]],"date-time":"2011-02-04T09:18:43Z","timestamp":1296811123000},"page":"278-288","source":"Crossref","is-referenced-by-count":28,"title":["Human growth hormone: New delivery systems, alternative routes of administration, and their pharmacological relevance"],"prefix":"10.1016","volume":"78","author":[{"given":"J.","family":"C\u00e1zares-Delgadillo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ganem-Rondero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.N.","family":"Kalia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2011.01.006_b0005","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11102-006-9079-5","article-title":"Complex rhythmicity of growth hormone secretion in humans","volume":"9","author":"Surya","year":"2006","journal-title":"Pituitary"},{"key":"10.1016\/j.ejpb.2011.01.006_b0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1172\/JCI2908","article-title":"Regulatory mechanisms of growth hormone secretion are sexually dimorphic","volume":"102","author":"Jaffe","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejpb.2011.01.006_b0015","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1210\/jc.2003-030246","article-title":"Sexual dimorphism of growth hormone (GH) regulation in humans: endogenous GH-releasing hormone maintains basal GH in women but not in men","volume":"88","author":"Jessup","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2011.01.006_b0020","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1210\/jc.77.2.356","article-title":"Analysis of 24-hour plasma profiles of growth hormone (GH)-binding protein, GH\/GH-binding protein-complex, and GH in healthy children","volume":"77","author":"Carlsson","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2011.01.006_b0025","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1210\/jc.74.4.801","article-title":"The definition of a spontaneous growth hormone (GH) peak: studies in normally growing and GH-deficient children","volume":"74","author":"Zadik","year":"1992","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2011.01.006_b0030","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000071232","article-title":"A tripeptidyl ensemble perspective of interactive control of growth hormone secretion","volume":"60","author":"Veldhuis","year":"2003","journal-title":"Horm. Res."},{"key":"10.1016\/j.ejpb.2011.01.006_b0035","first-page":"58","article-title":"Ghrelin, from GH secretagogue to orexigenic peptide","volume":"8","author":"Zizzari","year":"2004","journal-title":"Correspondances en Metabolismes, Hormones, Diabetes et Nutrition"},{"key":"10.1016\/j.ejpb.2011.01.006_b0040","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1210\/jcem-67-6-1186","article-title":"Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion","volume":"67","author":"Alba-Roth","year":"1988","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2011.01.006_b0045","unstructured":"T. E. Oggle, A. Costoff, Endocrinology, Medical College of Georgia, Georgia, US, 2007."},{"key":"10.1016\/j.ejpb.2011.01.006_b0050","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00128072-200204010-00005","article-title":"The use of somatropin (recombinant growth hormone) in children of short stature","volume":"4","author":"Mehta","year":"2002","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.ejpb.2011.01.006_b0055","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S1096-6374(00)80014-3","article-title":"Effects of growth hormone treatment in children with Prader\u2013Willi syndrome","volume":"10","author":"Lee","year":"2000","journal-title":"Growth Horm. IGF Res."},{"key":"10.1016\/j.ejpb.2011.01.006_b0060","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000053092","article-title":"Safety of high doses of recombinant human growth hormone","volume":"49","author":"Van Loon","year":"1998","journal-title":"Horm. Res."},{"key":"10.1016\/j.ejpb.2011.01.006_b0065","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1210\/jc.85.10.3720","article-title":"Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections","volume":"85","author":"Amato","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2011.01.006_b0070","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1210\/jc.82.7.2215","article-title":"Preservation of growth hormone pulsatility despite pituitary pathology, surgery, and irradiation","volume":"82","author":"Toogood","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2011.01.006_b0075","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1210\/jc.86.3.1222","article-title":"Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition and bone and lipoprotein metabolism in GH-deficient adults","volume":"86","author":"Laursen","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2011.01.006_b0080","unstructured":"F. a. D. Administration, Approved drug products with therapeutic equivalence evaluations, FDA, 2009."},{"key":"10.1016\/j.ejpb.2011.01.006_b0085","unstructured":"Eli Lilly and Company, Humatrope\u00ae somatropin (rDNA origin) for injection, 2009."},{"key":"10.1016\/j.ejpb.2011.01.006_b0090","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1210\/jc.82.11.3612","article-title":"Metabolic effects and pharmacokinetics of a growth hormone pulse in healthy adults: relation to age, sex, and body composition","volume":"82","author":"Vahl","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2011.01.006_b0095","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1530\/EJE-07-0057","article-title":"Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration","volume":"156","author":"Keller","year":"2007","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ejpb.2011.01.006_b0370","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0022-3565(24)38301-6","article-title":"A pharmacokinetic\/pharmacodynamic model for recombinant human growth hormone effects on induction of insulin-like growth factor I in monkeys","volume":"289","author":"Sun","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejpb.2011.01.006_b0105","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1365-2265.2006.02733.x","article-title":"Growth hormone distribution kinetics are markedly reduced in adults with growth hormone deficiency","volume":"66","author":"Catalina","year":"2007","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"Suppl. 2","key":"10.1016\/j.ejpb.2011.01.006_b0110","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1515\/JPEM.2002.15.S2.715","article-title":"A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency","volume":"15","author":"Silverman","year":"2002","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2011.01.006_b0115","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s11095-005-6021-x","article-title":"Novel long-acting crystal formulation of human growth hormone","volume":"22","author":"Govardhan","year":"2005","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2011.01.006_b0120","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1023\/A:1011951626286","article-title":"A large-scale process to produce microencapsulated proteins","volume":"15","author":"Herbert","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2011.01.006_b0125","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1210\/jc.2006-0514","article-title":"Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency","volume":"91","author":"Bidlingmaier","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"Suppl. 4","key":"10.1016\/j.ejpb.2011.01.006_b0130","first-page":"30","article-title":"First in human study of pegylated recombinant human growth hormone","volume":"65","author":"Harris","year":"2006","journal-title":"Horm. Res."},{"key":"10.1016\/j.ejpb.2011.01.006_b0135","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1080\/00498250802413856","article-title":"PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans","volume":"38","author":"Webster","year":"2008","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejpb.2011.01.006_b0140","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1210\/jc.86.10.4700","article-title":"A multicenter study of the efficacy and safety of sustained release GH in the treatment of naive pediatric patients with GH deficiency","volume":"86","author":"Reiter","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2011.01.006_b0145","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1210\/jc.2002-020480","article-title":"The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adults","volume":"87","author":"Cook","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2011.01.006_b0150","doi-asserted-by":"crossref","first-page":"6431","DOI":"10.1210\/jc.2005-0928","article-title":"Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency","volume":"90","author":"Hoffman","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2011.01.006_b0155","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jconrel.2009.03.014","article-title":"Development of a sustained-release recombinant human growth hormone formulation","volume":"137","author":"Kwak","year":"2009","journal-title":"J. Controlled Release"},{"issue":"Suppl. 4","key":"10.1016\/j.ejpb.2011.01.006_b0160","first-page":"148","article-title":"The pharmacokinetics, pharmacodynamics and safety of pegylated recombinant human growth hormone after single subcutaneous injections in adult male patients with growth hormone deficiency","volume":"65","author":"Abs","year":"2006","journal-title":"Horm. Res."},{"key":"10.1016\/j.ejpb.2011.01.006_b0165","unstructured":"R. Xie, E. Didier, P.E. Harris, P.A. Milligan, M.O. Karlsson, Population pharmacokinetic\/pharmacodynamic analysis for pegylated recombinant human growth hormone (PHA-794428) in healthy male volunteers, 88th Annual Meeting of the Endocrine Society Program and Abstracts, Boston, MA, 2006."},{"key":"10.1016\/j.ejpb.2011.01.006_b0170","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/EJE-09-0422","article-title":"Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH","volume":"161","author":"Touraine","year":"2009","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ejpb.2011.01.006_b0175","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1210\/en.2006-1170","article-title":"A long-acting, mono-PEGylated human growth hormone analog is a potent stimulator of weight gain and bone growth in hypophysectomized rats","volume":"148","author":"Cox","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejpb.2011.01.006_b0180","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1021\/bc800281s","article-title":"A new PEG-beta-alanine active derivative for releasable protein conjugation","volume":"19","author":"Pasut","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejpb.2011.01.006_b0185","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1515\/JPEM.2001.14.5.497","article-title":"A history of growth hormone injection devices","volume":"14","author":"Fidotti","year":"2001","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2011.01.006_b0190","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1472-6823-6-5","article-title":"Understanding and meeting the needs of those using growth hormone injection devices","volume":"6","author":"Dumas","year":"2006","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.ejpb.2011.01.006_b0195","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1177\/009127002762491361","article-title":"Pharmacokinetics and pharmacodynamics of a new formulation of recombinant human growth hormone administered by ZomaJet 2 Vision, a new needle-free device, compared to subcutaneous administration using a conventional syringe","volume":"42","author":"Agerso","year":"2002","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2011.01.006_b0200","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/08035259850157589","article-title":"Psychological responses to the needle-free Medi-Jector or the multidose Disetronic injection pen in human growth hormone therapy","volume":"87","author":"Verrips","year":"1998","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ejpb.2011.01.006_b0205","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1515\/JPEM.2003.16.3.383","article-title":"Are needle-free injections a useful alternative for growth hormone therapy in children? Safety and pharmacokinetics of growth hormone delivered by a new needle-free injection device compared to a fine gauge needle","volume":"16","author":"Dorr","year":"2003","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2011.01.006_b0210","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1472-6904-7-10","article-title":"Pharmacokinetics of recombinant human growth hormone administered by cool.click 2, a new needle-free device, compared with subcutaneous administration using a conventional syringe and needle","volume":"7","author":"Brearley","year":"2007","journal-title":"BMC Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2011.01.006_b0215","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-3659(02)00363-2","article-title":"Nasal drug delivery-possibilities, problems and solutions","volume":"87","author":"Illum","year":"2003","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.ejpb.2011.01.006_b0220","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0378-5173(94)90439-1","article-title":"Intranasal permeation of thyrotropin-releasing hormone: in vitro study of permeation and enzymatic degradation","volume":"107","author":"Jorgensen","year":"1994","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2011.01.006_b0225","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/jps.2600751113","article-title":"Intranasal administration of peptides: nasal deposition, biological response, and absorption of desmopressin","volume":"75","author":"Harris","year":"1986","journal-title":"J. Pharm. Sci."},{"year":"1998","series-title":"Bioadhesive Formulations for Nasal Peptide Delivery","author":"Illum","key":"10.1016\/j.ejpb.2011.01.006_b0230"},{"key":"10.1016\/j.ejpb.2011.01.006_b0235","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1211\/0022357011775145","article-title":"The biopharmaceutical aspects of nasal mucoadhesive drug delivery","volume":"53","author":"Ugwoke","year":"2001","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2011.01.006_b0240","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1023\/A:1015885204249","article-title":"The effect of sodium tauro-24,25-dihydrofusidate on the nasal absorption of human growth hormone in three animal models","volume":"7","author":"Baldwin","year":"1990","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2011.01.006_b0245","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1210\/jc.76.4.962","article-title":"Intranasal administration of human growth hormone (hGH) in combination with a membrane permeation enhancer in patients with GH deficiency: a pharmacokinetic study","volume":"76","author":"Hedin","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2011.01.006_b0250","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0378-5173(91)90231-C","article-title":"Effect of l-\u03b1-lysophosphatidylcholine on the nasal absorption of human growth hormone in three animal species","volume":"74","author":"Fisher","year":"1991","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2011.01.006_b0255","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0378-5173(90)90126-O","article-title":"Investigation of the nasal absorption of biosynthetic human growth hormone in sheep \u2013 use of a bioadhesive microsphere delivery system","volume":"63","author":"Illum","year":"1990","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2011.01.006_b0260","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1002\/jps.2600831212","article-title":"Epithelial transport and bioavailability of intranasally administered human growth hormone formulated with the absorption enhancers didecanoyl-l-\u03b1-phosphatidylcholine and \u03b1-cyclodextrin in rabbits","volume":"83","author":"Agerholm","year":"1994","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2011.01.006_b0265","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/eje.0.1350309","article-title":"Bioavailability and bioactivity of three different doses of nasal growth hormone (GH) administered to GH-deficient patients: comparison with intravenous and subcutaneous administration","volume":"135","author":"Laursen","year":"1996","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ejpb.2011.01.006_b0270","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1002\/jps.20069","article-title":"Thiomers in noninvasive polypeptide delivery: in vitro and in vivo characterization of a polycarbophil-cysteine\/glutathione gel formulation for human growth hormone","volume":"93","author":"Leitner","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2011.01.006_b0275","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jconrel.2004.08.001","article-title":"Nasal delivery of human growth hormone: in vitro and in vivo evaluation of a thiomer\/glutathione microparticulate delivery system","volume":"100","author":"Leitner","year":"2004","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.ejpb.2011.01.006_b0280","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejps.2005.03.014","article-title":"Intranasal delivery of recombinant human growth hormone (somatropin) in sheep using chitosan-based powder formulations","volume":"26","author":"Cheng","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2011.01.006_b0285","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/rr58","article-title":"The lung as a route for systemic delivery of therapeutic proteins and peptides","volume":"2","author":"Agu","year":"2001","journal-title":"Respir. Res."},{"key":"10.1016\/j.ejpb.2011.01.006_b0290","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrd2153","article-title":"Inhaling medicines: delivering drugs to the body through the lungs","volume":"6","author":"Patton","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2011.01.006_b0295","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/jam.1998.11.197","article-title":"Safety of inhaled proteins for therapeutic use","volume":"11","author":"Wolff","year":"1998","journal-title":"J. Aerosol. Med."},{"key":"10.1016\/j.ejpb.2011.01.006_b0300","doi-asserted-by":"crossref","first-page":"L1002","DOI":"10.1152\/ajplung.00260.2003","article-title":"Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules","volume":"286","author":"Lombry","year":"2004","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.ejpb.2011.01.006_b0305","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v12.i2-3.20","article-title":"Delivery of biotherapeutics by inhalation aerosol","volume":"12","author":"Niven","year":"1995","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.ejpb.2011.01.006_b0310","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0168-3659(94)90071-X","article-title":"Overcoming enzymatic and absorption barriers to non-parenterally administered protein and peptide drugs","volume":"29","author":"Zhou","year":"1994","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.ejpb.2011.01.006_b0315","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0378-5173(99)00295-1","article-title":"Proteolytic enzymes as a limitation for pulmonary absorption of insulin: in vitro and in vivo investigations","volume":"192","author":"Shen","year":"1999","journal-title":"Int. J. Pharm."},{"issue":"Suppl. A","key":"10.1016\/j.ejpb.2011.01.006_b0320","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0954-6111(97)90100-1","article-title":"Is total particle dose more important than particle distribution?","volume":"91","author":"Chrystyn","year":"1997","journal-title":"Respir. Med."},{"key":"10.1016\/j.ejpb.2011.01.006_b0325","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1677\/joe.0.1340197","article-title":"Lung to blood passage of human growth hormone after intratracheal instillation: stimulation of growth in hypophysectomized rats","volume":"134","author":"Folkesson","year":"1992","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.ejpb.2011.01.006_b0330","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1023\/A:1016292232513","article-title":"The influence of regional deposition on the pharmacokinetics of pulmonary-delivered human growth hormone in rabbits","volume":"12","author":"Colthorpe","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2011.01.006_b0335","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1023\/A:1015851521551","article-title":"The pharmacokinetics of pulmonary-delivered insulin: a comparison of intratracheal and aerosol administration to the rabbit","volume":"9","author":"Colthorpe","year":"1992","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2011.01.006_b0340","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jconrel.2004.01.027","article-title":"Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats","volume":"96","author":"Bosquillon","year":"2004","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.ejpb.2011.01.006_b0345","unstructured":"R.K. Wolff, Personal Communication, The International Society for Aerosols in Medicine Congress, 2003."},{"key":"10.1016\/j.ejpb.2011.01.006_b0350","doi-asserted-by":"crossref","first-page":"5176","DOI":"10.1002\/jps.21353","article-title":"Effect of dimethyl-beta-cyclodextrin concentrations on the pulmonary delivery of recombinant human growth hormone dry powder in rats","volume":"97","author":"Jalalipour","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2011.01.006_b0355","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1517\/17425247.2.3.533","article-title":"Emerging strategies for the transdermal delivery of peptide and protein drugs","volume":"2","author":"Schuetz","year":"2005","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2011.01.006_b0360","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s11095-005-2498-6","article-title":"Transdermal delivery of human growth hormone through RF-microchannels","volume":"22","author":"Levin","year":"2005","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2011.01.006_b0365","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1248\/bpb.31.1631","article-title":"Self-dissolving micropiles for the percutaneous absorption of recombinant human growth hormone in rats","volume":"31","author":"Ito","year":"2008","journal-title":"Biol. Phar. Bull."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641111000130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641111000130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T10:54:23Z","timestamp":1740912863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641111000130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0939641111000130"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2011.01.006","relation":{},"ISSN":["0939-6411"],"issn-type":[{"type":"print","value":"0939-6411"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}